RBC Capital Maintains Outperform on Regenxbio, Lowers Price Target to $17

Benzinga · 08/08 18:31
RBC Capital analyst Luca Issi maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $21 to $17.